MedPath

Efficacy of Flash Glucose-Sensing Technology on the Occurrence of Cardiac Arrhythmias Associated With Hypoglycemia

Not Applicable
Conditions
Insulin Treated Type 2 Diabetes With High Risk of Hypoglycemia
Interventions
Device: Usual self monitoring Blood Glucose device
Device: FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System
Registration Number
NCT03570138
Lead Sponsor
Poitiers University Hospital
Brief Summary

Hypoglycemia, frequently asymptomatic, may lead to cardiac arrythmias and induce an increased risk of cardiovascular morbidity and mortality in patients with type 2 diabetes (T2D). The study hypothesize is that the hypoglycemia reduction, achieved with the FREESTYLE LIBRE device, a Glucose Continuous Monitoring system, may decrease cardiac arrythmias associated with hypoglycemia. So the main objective is to evaluate the efficacy of the FREESTYLE LIBRE system, associated with a specific therapeutic education on the cardiac arrythmias reduction, compared to a capillary ASG system with standard therapeutic education, in patient with T2D with high risk of hypoglycemia.

This is a open, multicenter, controlled, randomized study in parallel group.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Standard self monitoring blood glucose systemUsual self monitoring Blood Glucose deviceParticipants will use their own usual self monitoring blood glucose system and receive a C They will wear a masked FREESTYLE LIBRE Pro system.
Flash continuous glucose monitoring systemFREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring SystemParticipants will wear the FREESTYLE LIBRE device and receive a specific therapeutic education for its use.
Primary Outcome Measures
NameTimeMethod
Prevalence of cardiac arrythmic events during a 14 days Continuous ECG Monitoring14 days

Cardiac arrythmic events :

* Bradycardia \< 45 bpm for ≥ 10 seconds

* or Asystole ≥ 3 seconds

* or Atrial Fibrillation ≥ 30 seconds

* or Non-sustained ventricular tachycardia defined as runs of beats arising from the ventricles with duration between 3 beats and 30 s with QRS ≥ 120ms and with RR intervall ≤ 600 ms (\>100 bpm)

Secondary Outcome Measures
NameTimeMethod
Prevalence of each component of the primary outcome14 days
Mean QT intervalFirst 24 hours
Prevalence of ≥ 5 minutes Atrial Fibrillation episodes14 days
Prevalence of ventricular extrasystolesFirst 24 hours

Trial Locations

Locations (7)

University Hospital, Bordeaux

🇫🇷

Bordeaux, France

University Hospital, Nantes

🇫🇷

Nantes, France

Hospital, Pau

🇫🇷

Pau, France

University Hospital, Toulouse

🇫🇷

Toulouse, France

University Hospital, Limoges

🇫🇷

Limoges, France

Hospital, Niort

🇫🇷

Niort, France

University Hospital, Poitiers

🇫🇷

Poitiers, France

© Copyright 2025. All Rights Reserved by MedPath